Literature DB >> 22270233

Low-threshold monopolar motor mapping for resection of primary motor cortex tumors.

Kathleen Seidel1, Jürgen Beck, Lennart Stieglitz, Philippe Schucht, Andreas Raabe.   

Abstract

BACKGROUND: Microsurgery within eloquent cortex is a controversial approach because of the high risk of permanent neurological deficit. Few data exist showing the relationship between the mapping stimulation intensity required for eliciting a muscle motor evoked potential and the distance to the motor neurons; furthermore, the motor threshold at which no deficit occurs remains to be defined.
OBJECTIVE: To evaluate the safety of low threshold motor evoked potential mapping for tumor resection close to the primary motor cortex.
METHODS: Fourteen patients undergoing tumor surgery were included. Motor threshold was defined as the stimulation intensity that elicited motor evoked potentials from target muscles (amplitude > 30 μV). Monopolar high-frequency motor mapping with train-of-5 stimuli (HF-TOF; pulse duration = 500 microseconds; interstimulus interval = 4.0 milliseconds; frequency = 250 Hz) was used to determine motor response--negative sites where incision and dissection could be performed. At sites negative to 3-mA HF-TOF stimulation, the tumor was resected.
RESULTS: HF-TOF mapping localized the motor neurons within the precentral gyrus by using variable, low-stimulation intensities. The lowest motor thresholds after final resection ranged from 3 to 6 mA, indicating close proximity of motor neurons. Postoperatively, 12 patients had no new motor deficit, 1 patient had a minor new temporary deficit (M4+, National Institutes of Health Stroke Scale 1), and another patient had a minor new permanent deficit (M4+, National Institutes of Health Stroke Scale 2). Thirteen patients had complete or gross total resection.
CONCLUSION: These preliminary data demonstrate that a monopolar HF-TOF threshold > 3 mA was not associated with a significant new motor deficit.

Entities:  

Mesh:

Year:  2012        PMID: 22270233     DOI: 10.1227/NEU.0b013e31824c02a0

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  7 in total

Review 1.  Essential Management of Pediatric Brain Tumors.

Authors:  Katharina Lutz; Stephanie T Jünger; Martina Messing-Jünger
Journal:  Children (Basel)       Date:  2022-04-02

2.  Continuous dynamic mapping to avoid accidental injury of the facial nerve during surgery for large vestibular schwannomas.

Authors:  Kathleen Seidel; Matthias S Biner; Irena Zubak; Jonathan Rychen; Jürgen Beck; Andreas Raabe
Journal:  Neurosurg Rev       Date:  2018-10-26       Impact factor: 3.042

3.  Monopolar 250-500 Hz language mapping: Results of 41 patients.

Authors:  S M Verst; P H P de Aguiar; M A S Joaquim; V G Vieira; A B C Sucena; M V C Maldaun
Journal:  Clin Neurophysiol Pract       Date:  2018-12-10

4.  Minimally invasive approach to a deep-seated motor eloquent brain tumour: a technical note.

Authors:  Jose Pedro Lavrador; Anna Oviedova; Noemia Pereira; Sabina Patel; Kapil Mohan Rajwani; Priya Sekhon; Richard Gullan; Keyoumars Ashkan; Francesco Vergani; Ranjeev Bhangoo
Journal:  J Surg Case Rep       Date:  2022-01-21

5.  Introduction of a novel connection clip for the ultrasonic aspirator for subcortical continuous motor mapping.

Authors:  Colette Boëx; Cristina Goga; Nadia Bérard; Julien Haemmerli; Gregory Zegarek; Andrea Bartoli; Shahan Momjian; Karl Schaller
Journal:  Brain Spine       Date:  2021-07-28

6.  Early re-do surgery for glioblastoma is a feasible and safe strategy to achieve complete resection of enhancing tumor.

Authors:  Philippe Schucht; Michael Murek; Astrid Jilch; Kathleen Seidel; Ekkehard Hewer; Roland Wiest; Andreas Raabe; Jürgen Beck
Journal:  PLoS One       Date:  2013-11-13       Impact factor: 3.240

7.  Multi-modal glioblastoma segmentation: man versus machine.

Authors:  Nicole Porz; Stefan Bauer; Alessia Pica; Philippe Schucht; Jürgen Beck; Rajeev Kumar Verma; Johannes Slotboom; Mauricio Reyes; Roland Wiest
Journal:  PLoS One       Date:  2014-05-07       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.